---
title: Effects of Graptopetalum Paraguayense E. Walther on the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome
nct_id: NCT01463748
overall_status: COMPLETED
phase: PHASE2, PHASE3
sponsor: Chung Shan Medical University
study_type: INTERVENTIONAL
primary_condition: Metabolic Syndrome
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01463748.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01463748"
ct_last_update_post_date: 2013-07-03
last_seen_at: "2026-05-12T06:44:35.513Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effects of Graptopetalum Paraguayense E. Walther on the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome

**NCT ID:** [NCT01463748](https://clinicaltrials.gov/study/NCT01463748)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 54
- **Lead Sponsor:** Chung Shan Medical University
- **Collaborators:** National Science and Technology Council, Taiwan
- **Conditions:** Metabolic Syndrome
- **Start Date:** 2011-07
- **CT.gov Last Update:** 2013-07-03

## Brief Summary

Metabolic syndrome (MS) is a significant risk factor of cardiovascular disease. The purposes of this study are going to investigate the effects of Graptopetalum paraguayense E. Walther on the oxidative stress, antioxidant enzyme activity and inflammation in subjects with metabolic syndromerelation. The investigators will recruit MS patients(n=50)and the inclusion criteria of MS are according to the Bureau of Health Promotion, Department of Health in Taiwan (2007). The MS subjects are randomly assigned to placebo(n=25) and Graptopetalum paraguayense E. Walther supplements(n=25)groups. Hopefully, the results of this study could provide the information of Graptopetalum paraguayense E. Walther supplements to what has been know in MS subjects.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* The inclusion criteria of MS in adult are according to the Bureau of Health Promotion, Department of Health in Taiwan (2007), if subjects had 3 of the following 5 characteristics: (1) abdominal obesity (waist circumference \>= 90 cm in men and \>= 80 cm in women), (2) impaired fasting glucose ( \>= 5.6 mmol/L), (3) hypertriglyceridemia ( \>= 1.7 mmol/L), (4) low HDL-C (\< 1.0 mmol/L in men and \< 1.3 mmol/L in women), and (5) increased blood pressure (SBP \>= 130 mmHg and DBP \>= 85 mmHg). Subjects using antidiabetic or antihypertensive or lipid-lowering medications were considered to have elevated fasting blood glucose or elevated blood pressures or dyslipidemia, respectively.

Exclusion Criteria:

* Subjects with liver, renal diseases, undergoing statin therapy, pregnancy women, and taking antioxidant vitamins supplements were excluded.
```

## Arms

- **Placebo** (EXPERIMENTAL) — starch
- **Graptopetalum paraguayense E. Walther** (EXPERIMENTAL) — Graptopetalum paraguayense E. Walther

## Interventions

- **Graptopetalum paraguayense E. Walther** (OTHER) — Graptopetalum paraguayense E. Walther
- **Placebo** (OTHER) — starch

## Primary Outcomes

- **Antioxidant and inflammation** _(time frame: 12 weeks)_ — The study are going to measure the concentrations of lipid peroxidation markers (TBARS and ox-LDL) and antioxidant enzymes activities (catalase, glutathione peroxidase, and superoxide dismutase), and the level of inflammatory markers (hs-CRP, TNF-alfa, IL-1, IL-6 and adiponectin) in all subjects of this study.

## Secondary Outcomes

- **Blood biochemical values** _(time frame: 12 weeks)_

## Locations (1)

- Chung Shan Medical University, Taichung, Taiwan

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chung shan medical university|taichung||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01463748.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01463748*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*